# US 10,370,642 B2 · Hematopoietic progenitor cell populations having affinity for E-selectin / L-selectin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,642 B2
- Document ID: US10370642B2
- Status: Granted
- Kind: B2
- Application number: 14/599,211
- Filed: 2015-01-16
- Published: 2016-07-14
- Granted: 2019-08-06
- Earliest claimed: 2000-10-18
- Assignees: Robert Sackstein
- Applicants: Robert Sackstein
- Inventors: Robert Sackstein
- Web page: https://patentgrep.com/patent/US10370642B2

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/16: Anti-Parkinson drugs
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/70585: {CD44}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2501/59: Lectins
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2501/724: Glycosyltransferases (EC 2.4.)
- C12N 2501/90: Polysaccharides
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.

## Claims

### Claim 1

A method of increasing the engraftment potential of a hematopoietic progenitor cell population, the method comprising: (a) providing said hematopoietic progenitor cell population; and (b) contacting said hematopoietic progenitor cell population with a recombinant expression vector comprising a nucleic acid encoding one or more of CD44 polypeptide, α(2,3) sialyltransferase, α(1,3)-fucosyltransferase, or combinations thereof, wherein the nucleic acid encodes a polypeptide that increases binding activity of the hematopoietic progenitor cell population for E-selectin and/or L-selectin, thereby increasing the engraftment potential of the hematopoietic progenitor cell population.

### Claim 2 (depends on 1)

The method of claim 1, wherein the α(1,3)-fucosyltransferase is α(1,3)-fucosyltransferase VII (FTVII).

### Claim 3 (depends on 1)

The method of claim 1, wherein the α(2,3)-sialyltransferase is α(2,3)-sialyltransferase ST3GalIV.

### Claim 4

A population of hematopoietic progenitor cells having a glycosylated polypeptide, said glycosylated polypeptide comprising a CD44 polypeptide that displays sialylated, fucosylated glycans that bind E-selectin and L-selectin, the population having a recombinant expression vector comprising a nucleic acid encoding one or more of CD44 polypeptide, α(2,3) sialyltransferase, α(1,3)-fucosyltransferase, or combinations thereof, wherein the nucleic acid increases binding activity of the population for E-selectin and/or L-selectin.

### Claim 5

A population of ex vivo modified hematopoietic progenitor cells having HCELL activity produced by contacting, ex vivo, a hematopoietic cell population comprising hematopoietic cells having little to no HCELL activity with one or more agents that increases cell-surface expression or activity of a HCELL polypeptide on the cell surface, the agent comprising one or more of α(2,3) sialyltransferase, α(1,3)-fucosyltransferase, or combinations thereof, wherein the agent increases affinity of the population for E-selectin and/or L-selectin.

### Claim 6 (depends on 4)

The population of claim 4, wherein the α(1,3)-fucosyltransferase is α(1,3)-fucosyltransferase VII (FTVII).

### Claim 7 (depends on 4)

The population of claim 4, wherein the α(2,3)-sialyltransferase is sialyltransferase ST3GalIV.

### Claim 8 (depends on 3)

The population of claim 3, wherein the α(1,3)-fucosyltransferase is α(1,3)-fucosyltransferase VII (FTVII).

### Claim 9 (depends on 3)

The population of claim 3, wherein the α(2,3)-sialyltransferase is sialyltransferase ST3GalIV.